Market Overview

XenoPort Reports Feedback from FDA on XP23829

Share:

XenoPort (NASDAQ: XNPT) today reported an update on XP23289 development,
including feedback from the U.S. Food and Drug Administration (FDA) on
the potential development plans, and XenoPort's progress on
commercializing HORIZANT® (gabapentin enacarbil)
Extended-Release Tablets.

XenoPort reported today that it received feedback from the FDA Division
of Neurology Products regarding potential development plans for XP23829
as a potential treatment for patients with relapsing forms of multiple
sclerosis (MS). Based on the feedback, XenoPort believes that the FDA
would allow XenoPort to initiate potential Phase 3 clinical development
using XP23829 doses that produce monomethyl fumarate (MMF) exposure
similar to that produced by the approved dose of TECFIDERA (dimethyl
fumarate).

See full press release

 

Related Articles (XNPT)

View Comments and Join the Discussion!

Posted-In: News Guidance Contracts FDA Management Global

Need corporate guidance data?
Click here to see licensing options.
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com